# EDGAR Filing Document

**Accession Number:** 0001820190
**File Stem:** 0001193125-26-288677
**Filing Date:** 2026-6
**Character Count:** 8825
**Document Hash:** f06f7d8ef7f2061e985cac52e7533cfa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-288677.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001193125-26-288677

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260624

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scilex Holding Co
- **CENTRAL INDEX KEY:** 0001820190
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39852
- **FILM NUMBER:** 261136694

**BUSINESS ADDRESS:**
- **STREET 1:** 960 SAN ANTONIO ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303
- **BUSINESS PHONE:** (650) 516-4310

**MAIL ADDRESS:**
- **STREET 1:** 960 SAN ANTONIO ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94303

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Scilex Holding Company/DE
- **DATE OF NAME CHANGE:** 20221117

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vickers Vantage Corp. I
- **DATE OF NAME CHANGE:** 20200804

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**_______________________**

**FORM** 8-K**_______________________**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported):** June 24, 2026

**_______________________** SCILEX HOLDING COMPANY **(Exact name of registrant as specified in its charter)_______________________**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Delaware**(State or other jurisdiction<br>of incorporation)** | &nbsp;&nbsp;001-39852**(Commission<br>File Number)** | &nbsp;&nbsp;92-1062542**(IRS Employer<br>Identification No.)** |

---

960 San Antonio Road**,** Palo Alto**,** California**,** 94303**(Address of principal executive offices, including zip code)**

**(**650**)** 516-4310

**Registrant's telephone number, including area code**

**N/A (Former Name or Former Address, if Changed Since Last Report)**

**_______________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**(Title of each class)** | &nbsp;&nbsp;**(Trading Symbol)** | &nbsp;&nbsp;**(Name of exchange on which registered)** |
| &nbsp;&nbsp;Common Stock, par value $0.0001 per share | &nbsp;&nbsp;SCLX | &nbsp;&nbsp;The Nasdaq Stock Market LLC |
| &nbsp;&nbsp;Warrants to purchase one share of common stock, each at an exercise price of $402.50 | &nbsp;&nbsp;SCLXW | &nbsp;&nbsp;The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

------

**Item 1.01. Entry into a Material Definitive Agreement.**

On June 24, 2026, Scilex Holding Company (the "Company") entered into a binding term sheet (the "Term Sheet") with Datavault AI Inc. ("Datavault"), which sets forth certain terms and conditions of the Company's proposed purchase (the "Proposed Transaction") of Bitcoin ("BTC") from Datavault that is currently held by Datavault in a Biconomy digital wallet (the "Wallet").

Pursuant to the Term Sheet, and subject to the finalization of a definitive agreement (the "Definitive Agreement") to be negotiated in good faith by the Company and Datavault and, ultimately, the satisfaction of certain customary closing conditions to be contained therein, it is expected that the Company will purchase from Datavault a total of 837 BTC held in the Wallet for $50 million (the "Purchase Price"). The Company has agreed to make an initial payment of $30 million, with the remaining $20 million payable in quarterly installments commencing in the fourth quarter of 2026 and ending on December 31, 2028. The Company will pay the Purchase Price in cash or shares of the Company's common stock, par value $0.0001 per share ("Company Common Stock") or publicly traded securities of the Company's subsidiaries, or a combination thereof, at the discretion of the Company.

The Term Sheet provides that the Definitive Agreement will contain customary representations, warranties, covenants, indemnities, limitations on indemnity, termination provisions and other terms typical for transactions of this nature.

There can be no assurance that the Definitive Agreement and any other transaction documents necessary to consummate the Proposed Transaction will be entered into, or that the Proposed Transaction will be consummated on the terms described herein or at all. The consummation of the Proposed Transaction is subject to numerous factors, many of which are outside the control of the Company, including market conditions, regulatory approvals, the actions of third parties, and the ability of the parties to negotiate and execute the Definitive Agreement. The Term Sheet reflects terms that remain subject to further negotiation, modification and/or approval by the applicable boards of directors and may be terminated by the parties. Any such termination, or a failure by the parties to agree on the Definitive Agreement, could result in disputes or litigation relating to the interpretation, enforceability and/or performance of the provisions of the Term Sheet, which could be costly and/or time-consuming, divert management attention and/or otherwise adversely affect the financial condition or liquidity of the Company, including its ability to pursue or defend such claims. Accordingly, investors should not place undue reliance on the consummation of the Proposed Transaction or the ability of the Company and Datavault to consummate the Proposed Transaction.

The foregoing description of the Term Sheet does not purport to be complete and is qualified in its entirety by reference to the full text of the Term Sheet, a copy of which the Company will file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026 or by an amendment to this Current Report on Form 8-K.

**Item 3.02. Unregistered Sales of Equity Securities.** 

The information provided in Item 1.01 regarding the Term Sheet and the potential issuance of shares of Company Common Stock is hereby incorporated by reference.

It has not yet been determined whether the shares of Company Common Stock that may be issued in the Proposed Transaction will be issued in a private placement. If such shares are issued in a private placement, the Company expects that (i) such shares would be issued to Datavault in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder and (ii) Datavault will represent that it is an "accredited investor," as defined in Regulation D, and will acquire such shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Neither this Current Report on Form 8-K nor the Term Sheet is an offer to sell or the solicitation of an offer to buy shares of Company Common Stock or any other securities of the Company.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SCILEX HOLDING COMPANY** | **SCILEX HOLDING COMPANY** |
|  | By: | /s/ Henry Ji, Ph.D.  |
|  | Name: | Henry Ji, Ph.D. |
| Date: June 29, 2026 | Title: | Chief Executive Officer & President |

---

------